Nothing Special   »   [go: up one dir, main page]

ES2051766T3 - Antigestagenos para la inhibicion de la sintesis uterina de prostaglandinas. - Google Patents

Antigestagenos para la inhibicion de la sintesis uterina de prostaglandinas.

Info

Publication number
ES2051766T3
ES2051766T3 ES87730107T ES87730107T ES2051766T3 ES 2051766 T3 ES2051766 T3 ES 2051766T3 ES 87730107 T ES87730107 T ES 87730107T ES 87730107 T ES87730107 T ES 87730107T ES 2051766 T3 ES2051766 T3 ES 2051766T3
Authority
ES
Spain
Prior art keywords
antigestagens
synthesis
prostaglandinas
uterine
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87730107T
Other languages
English (en)
Inventor
Walter Dr Elger
Marianne Dipl-Biologi Fahnrich
Sybille Dr Dipl-Biologin Beier
Krzysztof Dr Chwalisz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Application granted granted Critical
Publication of ES2051766T3 publication Critical patent/ES2051766T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

UTILIZACION DE ANTIGESTAGENOS PARA LA OBTENCION DE MEDICAMENTOS DE PROSTAGLANDINAS.
ES87730107T 1986-09-26 1987-09-15 Antigestagenos para la inhibicion de la sintesis uterina de prostaglandinas. Expired - Lifetime ES2051766T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19863633244 DE3633244A1 (de) 1986-09-26 1986-09-26 Antigestagene zur hemmung der uterinen prostaglandinsynthese

Publications (1)

Publication Number Publication Date
ES2051766T3 true ES2051766T3 (es) 1994-07-01

Family

ID=6310705

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87730107T Expired - Lifetime ES2051766T3 (es) 1986-09-26 1987-09-15 Antigestagenos para la inhibicion de la sintesis uterina de prostaglandinas.

Country Status (12)

Country Link
US (1) US5744464A (es)
EP (1) EP0266303B1 (es)
JP (1) JP2582088B2 (es)
AT (1) ATE78690T1 (es)
AU (1) AU605177B2 (es)
DE (2) DE3633244A1 (es)
DK (1) DK169162B1 (es)
ES (1) ES2051766T3 (es)
GR (1) GR3005467T3 (es)
IE (1) IE66196B1 (es)
IL (1) IL83967A (es)
ZA (1) ZA877247B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
FR2651435A1 (fr) * 1989-09-07 1991-03-08 Roussel Uclaf Nouvelle utilisation de composes anti-progestomimetiques.
FR2654337B1 (fr) * 1989-11-15 1994-08-05 Roussel Uclaf Nouvelles microspheres injectables biodegradables procede de preparation et suspensions injectables les renfermant.
DE19652408C2 (de) * 1996-12-06 2002-04-18 Schering Ag Steroidester, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Arzneimitteln
DE60036723T2 (de) 1999-08-31 2008-07-17 Bayer Schering Pharma Aktiengesellschaft Mesoprogestine zur behandlung und vorbeugung von hormonabhängigen gutartigen gynekologischen störungen
WO2010117639A2 (en) * 2009-03-31 2010-10-14 The Texas A&M University System Inhibition of prostglandin e2 receptors for the treatment of endometriosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3077437A (en) * 1957-07-29 1963-02-12 George P Heckel Pregnanediol for treatment of premenstrual syndrome
US3666858A (en) * 1967-06-29 1972-05-30 Gordon Alan Hughes Utilization of gon-4-ene therapy in treatment of females and in growth stimulation
US4780461A (en) * 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
DE3337450A1 (de) * 1983-10-12 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen Prostaglandine und antigestagene fuer den schwangerschaftsabbruch
DE3347126A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3625315A1 (de) * 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3702383A1 (de) * 1987-01-23 1988-08-04 Schering Ag 11ss-alkinylestrene und -estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate

Also Published As

Publication number Publication date
IE872578L (en) 1988-03-26
EP0266303B1 (de) 1992-07-29
DE3633244A1 (de) 1988-03-31
JPS63101326A (ja) 1988-05-06
GR3005467T3 (es) 1993-05-24
EP0266303A2 (de) 1988-05-04
JP2582088B2 (ja) 1997-02-19
DK487287A (da) 1988-03-27
DE3780757D1 (de) 1992-09-03
DK487287D0 (da) 1987-09-16
AU7895087A (en) 1988-03-31
IL83967A (en) 1992-11-15
ATE78690T1 (de) 1992-08-15
IL83967A0 (en) 1988-02-29
EP0266303A3 (en) 1989-12-20
DK169162B1 (da) 1994-09-05
US5744464A (en) 1998-04-28
IE66196B1 (en) 1995-12-13
AU605177B2 (en) 1991-01-10
ZA877247B (en) 1988-03-28

Similar Documents

Publication Publication Date Title
IT1101865B (it) Procedimento per la produzione di composti poliossidrilici a basso peso molecolare
ES2030409T3 (es) Procedimiento para preparar y purificar compuestos termolabiles .
ES546625A0 (es) Procedimiento para la sintesis de derivados de acidos omega-aminados
ES519982A0 (es) Procedimiento para preparar -monohidrato de (+)-catequina.
NO882506L (no) Poroes anordning for segmentert syntese av biopolymerer.
IT8720149A0 (it) Procedimento per la sintesi di acidi 2-aril-propionici.
IT7949147A0 (it) Procedimento per la sintesi di 16pregnani da 17-chetosteroidi
ES2051766T3 (es) Antigestagenos para la inhibicion de la sintesis uterina de prostaglandinas.
IT7949087A0 (it) Procedimento per la sintesi di 2idrossi-3-metil ciclopent-2-en-1one
FR2609463B1 (fr) Synthese des perfluoroalkyl-2 ethanethiols
ES2023930B3 (es) Sintesis de ditioles.
IT1155795B (it) Metodo di sintesi per la preparazione della 3,4,5-trimetossibenzaldeide
FR2593506B1 (fr) Procede de synthese de diorganomonothiophosphinates
AR222393A1 (es) Procedimiento para la sintesis de 2-isopropilamino-pirimidina
IT8621313A1 (it) Procedimento per la sintesi di alchil-vinil-eteri
IT8621033A1 (it) Procedimento per la sintesi di dialcossi propani
IT7967132A0 (it) Procedimento per la sintesi di 2benzensolfonamido 3 metossipirazina
IT8419324A0 (it) Procedimento per la sintesi di derivati n-acilici dell'aspartame.
MA20825A1 (fr) Procede de synthese de tetraalkyl-ethenylidenebis phosphonates
BE896743A (fr) Synthese de naphtacenequinone.
IT8622747A0 (it) Procedimento per la sintesi di dialcossi propani.
ES545276A0 (es) Procedimiento para la sintesis de neohesperidina dihidro- chalcona a partir de naringina
ES504263A0 (es) Procedimiento para la sintesis de n-bromometilato del ester tropico del n-isopropil-nortropan-3a-ol
IT1151184B (it) Procedimento per la sintesi di 2,4,6 trimetil-4 idrossicicloesa-2,5 dien-1 one
ES550885A0 (es) Procedimiento para la sintesis de 4,9-dihidro-4-(1-metil-4-piperidinilideno)-10-h-benzo (4,5) ciclohepta-(1,2-b) tiofeno-10-ona

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 266303

Country of ref document: ES